General American Investors Co. Inc. Sells 31,601 Shares of Tenet Healthcare Corporation $THC

General American Investors Co. Inc. trimmed its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 51.3% during the fourth quarter, HoldingsChannel reports. The firm owned 30,000 shares of the company’s stock after selling 31,601 shares during the quarter. General American Investors Co. Inc.’s holdings in Tenet Healthcare were worth $112,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of THC. Norges Bank bought a new stake in Tenet Healthcare during the 4th quarter worth approximately $248,494,000. Eminence Capital LP bought a new stake in Tenet Healthcare during the 3rd quarter worth approximately $225,263,000. Boston Partners increased its stake in Tenet Healthcare by 38.8% during the 3rd quarter. Boston Partners now owns 3,147,555 shares of the company’s stock worth $638,958,000 after purchasing an additional 880,413 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Tenet Healthcare by 62.3% during the 3rd quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock worth $380,989,000 after acquiring an additional 720,160 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of Tenet Healthcare by 375.7% during the 2nd quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock worth $139,085,000 after acquiring an additional 624,125 shares in the last quarter. 95.44% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Nadja West sold 3,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the sale, the director owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This represents a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director J Robert Kerrey sold 5,638 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the transaction, the director directly owned 16,804 shares of the company’s stock, valued at approximately $2,932,634.08. The trade was a 25.12% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.97% of the company’s stock.

Tenet Healthcare Trading Up 0.9%

Shares of Tenet Healthcare stock opened at $174.67 on Friday. The firm has a 50-day moving average of $183.94 and a 200-day moving average of $199.94. The stock has a market cap of $15.05 billion, a PE ratio of 9.08, a PEG ratio of 1.44 and a beta of 1.28. Tenet Healthcare Corporation has a 52-week low of $146.60 and a 52-week high of $247.21. The company has a debt-to-equity ratio of 1.96, a quick ratio of 1.30 and a current ratio of 1.36.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, April 30th. The company reported $4.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.21 by $0.61. The company had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.39 billion. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. Tenet Healthcare’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.36 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, sell-side analysts forecast that Tenet Healthcare Corporation will post 17.61 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on THC shares. Barclays decreased their price target on shares of Tenet Healthcare from $257.00 to $238.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a report on Wednesday, March 4th. KeyCorp decreased their price objective on Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Guggenheim decreased their price objective on Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Mizuho raised their price objective on Tenet Healthcare from $235.00 to $265.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Eighteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $244.16.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.